MedTrace Logo

Anti-Androgen Treatment for COVID-19

NCT04446429 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 268

Last updated 2021-12-10

Study results available
· View outcomes & findings →

Summary

This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection

Conditions

Interventions

DRUG

Proxalutamide

200 mg q.d.

OTHER

Standard of Care

Standard of care as determined by the PI

Sponsors & Collaborators

  • Applied Biology, Inc.

    lead INDUSTRY

Principal Investigators

  • Flavio A Cadegiani, MD · Corpometria Institute

  • Andy Goren, MD · Applied Biology, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-21
Primary Completion
2020-12-24
Completion
2021-01-21

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04446429 on ClinicalTrials.gov